Nevertheless, Cahill and colleagues [17] detected MSH6 mutations in 3 of 14 recurrent brain tumors, but no mutation of MSH6 in 40 pretreatment GBM, suggesting that loss of MSH6 expression might set in during temozolomide treatment. Here, MSH6 is linked to glioblastoma.